Artelo Biosciences, Inc. (ARTL)

USD 0.97

(17.95%)

Market Cap (In USD)

3.18 Million

Revenue (In USD)

-

Net Income (In USD)

-9.87 Million

Avg. Volume

23.26 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.94-1.75
PE
-0.32
EPS
-3.05
Beta Value
1.35
ISIN
US04301G5080
CUSIP
04301G201
CIK
1621221
Shares
3281030.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gregory D. Gorgas M.B.A.
Employee Count
-
Website
https://www.artelobio.com
Ipo Date
2019-06-21
Details
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.